Роль системы комплемента в патогенезе вирусной инфекции SARS-CoV-2 при психических заболеваниях
https://doi.org/10.30629/2618-6667-2021-19-4-76-89
Аннотация
Введение: система комплемента может быть критическим фактором, определяющим исход коронавирусной инфекции COVID-19. Для многих психических заболеваний характерно системное стерильное воспаление, обязательным участником которого является система комплемента. Цель: представить анализ научных данных о роли системы комплемента в патогенезе вирусных заболеваний и особенностей течения COVID-19 у психически больных. Материал и методы: с помощью ключевых слов «система комплемента и коронавирусная инфекция 2019», «ингибирование системы комплемента», «коронавирусная инфекция 2019 и психические заболевания» проводился поиск научных статей в базах данных MEDLINE, PubMed и других источниках. Заключение: пациенты с психическими заболеваниями относятся к группе риска в силу физиологических и ментальных особенностей, а инфицирование вирусом SARS-CoV-2 может провоцировать рецидив основного заболевания. Терапевтическое ингибирование системы комплемента поможет снизить этот риск и уменьшить вероятность тяжелых осложнений при системном воспалении, вызванном этой инфекцией.
Об авторах
Е. Г. Черемных
Научный центр психического здоровья
Россия
Россия
Елена Григорьевна Черемных, кандидат технических наук, лаборатория биохимии
Москва
П. А. Иванов
Научный центр психического здоровья
Россия
Россия
Павел Александрович Иванов, кандидат биологических наук, лаборатория нейроиммунологии
Москва
М. И. Фактор
Научный центр психического здоровья
Россия
Россия
Магнолия Иосифовна Фактор, кандидат биологических наук, лаборатория биохимии
Москва
А. Н. Позднякова
Научный центр психического здоровья
Россия
Россия
Анастасия Николаевна Позднякова, младший научный сотрудник, лаборатория нейрофизиологии
Москва
Ю. Е. Шилов
Научный центр психического здоровья
Россия
Россия
Юрий Евгеньевич Шилов, кандидат биологических наук, лаборатория биохимии
Москва
О. С. Брусов
Научный центр психического здоровья
Россия
Россия
Олег Сергеевич Брусов, кандидат биологических наук, заведующий лабораторией, лаборатория биохимии
Москва
Список литературы
1. Bohmwald K, Gálvez NMS, Ríos M, Kalergis AM. Neurologic Alterations Due to Respiratory Virus Infections Front. Cell. Neurosci. 2018;12:386. doi: 10.3389/fncel.2018.00386
2. Kwan WH, van der Touw W, Heeger PS. Complement regulation of T cell immunity. Immunol Res. 2012;54:247–253. doi: 10.1007/s12026-012-8327-1
3. Stephan AH, Barres BA, Stevens B. The Complement System: An Unexpected Role in Synaptic Pruning Development and disease. Annual Review of Neuroscience. 2012;35:369–389. http://doi.org/10.1146/annurev-neuro-061010-113810
4. Camous L, Roumenina L, Bigot S, Soumenya Brachemi, Fremeaux-Bacchi V, Lesavre P, Halbwachs-Mecarelli L. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood. 2011;117:1340–1349. http://doi.org/10.1182/blood-2010-05-283564
5. Hourcade DE. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J Biol Chem. 2006 Jan 27;281(4):2128–2132. doi: 10.1074/jbc.M508928200 Epub 2005 Nov 21. PMID: 16301317
6. Tenner AJ, Volkin DB. Complement subcomponent C1q secreted by cultured human monocytes has subunit structure identical with that of serum C1q. Biochem J. 1986; 233:451–458. doi: 10.1042/bj2330451
7. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–797. doi: 10.1038/ni.1923
8. Druart M, Le Magueresse C. Emerging Roles of Complement in Psychiatric Disorders. Front Psychiatry. 2019;10:573. doi: 10.3389/fpsyt.2019.00573 PMID: 31496960; PMCID: PMC6712161
9. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. Nat Rev Microbiol. 2008;6(2):132. doi: 10.1038/nrmicro182
10. Biro A, Rovo Z, Papp D, Cervenak L, Varga L, Fust G, Thielens NM, Arlaud GJ, Prohaszka Z. Studies on the interactions between C-reactive protein and complement proteins. Immunology. 2007;121(1):40–50. doi: 10.1111/j.1365-2567.2007.02535.x
11. Ricklin D, Reis ES, Mastellos DC, Gros P, Jambris JD. Complement component C3 — The “Swiss Army Knife” of innate immunity and host defense. Immunol Rev. 2016;274(1):33–58. doi: 10.1111/imr.12500
12. Sturfelt G, Truedsson L. Complement in the immunopathogenesis of rheumatic disease. Nature Reviews Rheumatology. 2012;8:458–468. doi: 10.1038/nrrheum.2012.75
13. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Brückner UB, Nilsson B, Gebhard F, Lambris JD, Huber-Lang M. Molecular Intercommunication between the Complement and Coagulation Systems. J Immunol. 2010;185:5628–5636. doi: 10.4049/jimmunol.0903678
14. Oikonomopoulou K, Ricklin D, Ward PA, Lambris JD. Interactions between coagulation and complement — their role in inflammation. Semin Immunopathol. 2012;34(1):151–165. doi: 10.1007/s00281-011-0280-x.
15. Landsem A, Fure H, Christiansen D, Nielsen EW, Osterud B, Mollnes TE, Brekke OL. The key roles of complement and tissue factor in Escherichia coli-induced coagulation in human whole blood. Clin. Exp. Immunol. 2015;182:81–89. doi: 10.1111/cei.12663
16. Krarup A, Wallis R, Presanis JS, Gál P, Sim RB. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS One 2(7):e623. doi: 10.1371/journal.pone.0000623
17. Hess K, Ajjan R, Phoenix F, Dobo J, Gál P., Schroeder V. Effects of MASP-1 of the complement system on activation of coagulation factors and plasma clot formation. PLoS One. 2012;7(4):e35690. doi: 10.1371/journal.pone.0035690
18. Fletcher-Sandersjooa A, Bellander BM. Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? Thrombosis Research. 2020;194:36–41. http://doi.org/10.1016/j.thromres.2020:06.027
19. Wallace EM, Perkins SM, Sim PB, Willis AC, Feighery C, Jackson J. Degradation of C1-inhibitor by plasmin: implications for the control of inammatory processes. Mol Med. 1997;3(6):385–396.
20. Foley JH, Walton BL, Aleman MM, O’Byrne AM, Lei V, Harrasser M, Foley KA, Wolberg AS, Conway EM. Complement activation in arterial and venous thrombosis is mediated by plasmin. EBioMedicine. 2016;5:175–182. doi: 10.1016/j.ebiom.2016.02.011
21. Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation. Circ. Res. 2016;118:1392–1408. doi: 10.1161/CIRCRESAHA.116.306853
22. Dobó J, Schroeder V, Jenny L, Cervenak L, Závodszky P, Gál P. Multiple roles of complement MASP-1 at the interface of innate immune response and coagulation. Mol Immunol. 2014;61:69–78. doi: 10.1016/j.molimm.2014.05.013
23. Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood. 1986;68:875–880.
24. Hamad OA, Bäck J, Nilsson PH, NilssonB, Ekdahl KN. Platelets, complement, and contact activation: partners in inflammation and thrombosis. Advances in Experimental Medicine and Biology. 2012;946:185–205. doi: 10.1007/978-1-4614-0106-3_11
25. Subramaniam S, Jurk K, Hobohm L, Jackel S, Saffarzadeh M, Schwierczek K, Wenzel P, Langer F, Reinhardt C, Ruf W. Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. Blood. 2017;129:2291–2302. doi: 10.1182/blood-2016-11-749879
26. Nilsson PH. Interaction between platelets and complement with implication for the regulation at surfaces. Doctoral dissertation, School of Natural Sciences, Linnaeus University 2012; ISBN: 978-91- 86983-46-8
27. Java A, Kim AHJ, Kulkarni HS. The complement system in COVID-19: friend and foe? JCI Insight. 2020; https://doi.org/10.1172/jci.insight.140711
28. Yang T, Xu C. Physiology and Pathophysiology of the Intrarenal Renin-Angiotensin System: An Update. J Am Soc Nephrol. 2017;28:1040–1049. doi: 10.1681/ASN.2016070734
29. Wiesea OJ, Allwoodb BW, Zemlin AE. COVID-19 and the renin-angiotensin system (RAS): A spark that sets the forest alight? Medical Hypotheses. 2020;144:110231. http://doi.org/10.1016/j.mehy.2020.110231
30. Shagdarsuren E, Wellner M, Braesen JH, Park JK, Fiebeler A, Henke N, Dechend R, Gratze P, Luft FC, Muller DN. Complement Activation in Angiotensin II-Induced Organ Damage. Circ Res. 2005;97:716–724. doi: 10.1161/01.RES.0000182677.89816.38
31. Stoermer KA, Morrison TE. Complement and viral pathogenesis. Virology. 2011;411:362–373. doi: 10.1016/j.virol.2010.12.045
32. Matricardi PM, Dal Negro RW, Nisini R. The first, holistic immunological model of COVID-19: Implications for prevention, diagnosis, and public health measures. Pediatr Allergy Immunol. 2020;31(5):454–470. doi: 10.1111/pai.13271 Epub 2020 Jun 5. PMID: 32359201; PMCID: PMC7267459
33. To KF, Lo AWI. Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). J Pathol. 2004;203:740–743. doi: 10.1002/path.1597
34. Anand P, Puranik A, Aravamudan M, Venkatakrishnan AJ, Soundararajan V. SARS-CoV-2 strategically mimics proteolytic activation of human EnaC. Cite as: eLife. 2020;9:e58603. doi: 10.7554/eLife.58603
35. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454. doi: 10.1038/nature02145
36. McBride R, Van Zyl M, Fielding BC. The Coronavirus Nucleocapsid Is a Multifunctional Protein. Viruses. 2014;6(8);2991–3018. https://doi.org/10.3390/v6082991
37. Risitano M, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD Complement as a target in COVID-19? Nat Rev Immunol. 2020;20(6):343–344. http://doi.org/10.1038/s41577-020-0320-7
38. Veerhuis R, Nielsen HM, Tenner AJ. Complement in the brain. Mol Immunol. 2011;48(14):1592–1603. doi: 10.1016/j.molimm.2011.04.003. Epub 2011 May 4. PMID: 21546088; PMCID: PMC3142281
39. Aiyaz M, Lupton MK, Proitsi P, Powell JF, Lovestone S. Complement activation as a biomarker for Alzheimer’s disease. Immunobiology. 2012;217(2):204–215. doi: 10.1016/j.imbio.2011.07.023
40. Mayilyan KR, Weinberger DR, Sim RB. The Complement System in Schizophrenia Drug. News Perspect. 2008;21(4):200–210. doi: 10.1358/dnp.2008.21.4.1213349
41. Oliveira J, Oliveira-Maia AJ, Tamouza R, Brown AS, Leboyer M. Infectious and immunogenetic factors in bipolar disorder. Acta Psychiatr Scand. 2017;136(4):409–423. doi: 10.1111/acps.12791
42. Corbett BA, Kantor AB, Schulman H, Walker WL, Lit L, Ashwood P, Rocke DM, Sharp FR. A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Mol Psychiatry. 2007;12(3):292–306. doi: 10.1038/sj.mp.4001943 Epub 2006 Dec 26. PMID: 17189958
43. Mongan D, Cannon M, Cotter DR. COVID-19, hypercoagulation and what it could mean for patients with psychotic disorders. Brain Behav Immun. 2020 Aug;88(2):9–10. doi: 10.1016/j.bbi.2020.05.067
44. Håvik B, Le Hellard S, Rietschel M, Lybæk H, Djurovic S, Mattheisen M, Mühleisen TW, Degenhardt F, Priebe L, Maier W, Breuer R, Schulze TG, Agartz I, Melle I, Hansen T, Bramham CR, Nöthen MM, Stevens B, Werge T, Andreassen OA, Cichon S, Steen Vidar M. The Complement Control-Related Genes CSMD1 and CSMD2 Associate to Schizophrenia. Biol Psychiatry. 2011;70:35–42. doi: 10.1016/j.biopsych
45. Good P. Evidence the U.S. autism epidemic initiated by acetaminophen (Tylenol) is aggravated by oral antibiotic amoxicillin/clavulanate (Augmentin) and now exponentially by herbicide glyphosate (Roundup). Clinical Nutrition. 2017;171–183. http://doi.org/10.1016/j.clnesp
46. Mayilyan KR, Dodds AW, Boyajyan AS, Soghoyan AF, Sim RB. Complement C4B protein in schizophrenia. World J Biol Psychiatry. 2008;9(3):225–230. doi: 10.1080/15622970701227803 PMID: 17853297
47. Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, Tooley K, Presumey J, Baum M, Van Doren V, Genovese G, Rose SA, Handsaker RE; Schizophrenia Working Group of the Psychiatric Genomics Consortium, Daly MJ, Carroll MC, Stevens B, McCarroll SA. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177–183. doi: 10.1038/nature16549 Epub 2016 Jan 27. PMID: 26814963; PMCID: PMC4752392
48. Najjar S, Pearlman DM, Alper K, Najjar A, Devinsky O. Neuro inflammation and psychiatric illness. J Neuroinflammation. 2013;10:43. doi: 10.1186/1742-2094- 10-43 PMID: 23547920; PMCID: PMC3626880.
49. Hoirisch-Clapauch S, Amaral OB, Mezzasalma MAU, Panizzutti R, Nardi AE. Dysfunction in the coagulation system and schizophrenia. Transl Psychiatry. 2016;6:e704. doi: 10.1038/tp.2015.204
50. English JA, Lopez LM, O’Gorman A, Föcking M, Hryniewiecka M, Scaife S, Sabherwal S, Wynne K, Dicker P, Rutten BPF, Lewis J, Cannon M, Cagney G, Cotter DR. Blood-Based Protein Changes in Childhood Are Associated With Increased Risk for Later Psychotic Disorder: Evidence From a Nested Case–Control Study of the ALSPAC Longitudinal Birth Cohort. Schizophr Bull. 2018;44(2):297–306. doi: 10.1093/schbul/sbx075
51. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. The Lancet Psychiatry. 2020. https://doi.org/10.1016/S2215-0366(20)30462-4
52. Noris M, Benigni A, Remuzzi G. The case of Complement activation in COVID-19 multiorgan impact. Kidney International. http://doi.org/10.1016/j.kint.2020.05.013
53. Thurman JM. Many drugs for many targets: novel treatments for complement-mediated glomerular disease. Nephrol Dial Transplant. 2017;32(1):i57–i64. doi: 10.1093/ndt/gfw228
54. Horiuchi T, Tsukamoto H. Complement-targeted therapy: development of C5- and C5a-targeted inhibition. Inflamm Regen. 2016;36:11. doi: 10.1186/s41232-016-0013-6 PMID: 29259684; PMCID: PMC5725830
55. Ricklin D, Lambris JD. Progress and trends in complement therapeutics. Adv Exp Med Biol. 2013;735:1–22. PMID: 23402016
56. Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A, De Negri P, Di Gennaro C, Pagano A, Allegorico E, Bressy L, Bosso G, Ferrara A, Serra C, Montisci A, D’Amico M, Schiano Lo Morello S, Di Costanzo G, Tucci AG, Marchetti P, Di Vincenzo U, Sorrentino I, Casciotta A, Fusco M, Buonerba C, Berretta M, Ceccarelli M, Nunnari G, Diessa Y, Cicala S, Facchini G. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040–4047. doi: 10.26355/eurrev_202004_20875 PMID: 32329881
Рецензия
Для цитирования:
Черемных Е.Г., Иванов П.А., Фактор М.И., Позднякова А.Н., Шилов Ю.Е., Брусов О.С. Роль системы комплемента в патогенезе вирусной инфекции SARS-CoV-2 при психических заболеваниях. ПСИХИАТРИЯ. 2021;19(4):76-89. https://doi.org/10.30629/2618-6667-2021-19-4-76-89
For citation:
Cheremnykh E.G., Ivanov P.A., Factor M.I., Pozdnyacova A.N., Shilov Y.E., Brusov O.S. The Role of the Complement System in the Pathogenesis of SARS-CoV-2 Viral Infection in Mental Illness. Psikhiatriya. 2021;19(4):76-89. (In Russ.) https://doi.org/10.30629/2618-6667-2021-19-4-76-89
Просмотров: 371
Послать статью по эл. почте 
